Health Care/Hospital
GV Regains Compliance with Nasdaq Minimum Bid Price Requirement
TORONTO, June 13, 2024 /PRNewswire/ -- Visionary Holdings Inc. (the "Company") (NASDAQ: GV), a private education provider with technology of artificial intelligence and life science on the cutting edge, with subsidiaries inCanada and market partners inChina, today announced the Company received a...
2024-06-13 20:30
3295
Latest Updates of Viva Biotech's Portfolio Companies
HONG KONG, June 12, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the suc...
2024-06-12 19:51
1895
2024ASCO｜Memorial Sloan Kettering Cancer Center (MSK)'s Prof. Wungki Park Unveils Precision Targeting of TF in Pancreatic Cancer, Signaling ADC Drug Innovations
Introduction: ADC Drug Breakthrough Targets TF in Pancreatic Cancer CHICAGO, June 12, 2024 /PRNewswire/ -- The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, held inChicago from May 31 to June 4, shone a spotlight on MRG004A, a novel antibody-drug conjugate (ADC) designed to tr...
2024-06-12 19:31
1291
Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono)
OSAKA, Japan and WALTHAM, Mass., June 11, 2024 /PRNewswire/ -- Ono Pharmaceutical, Co., Ltd. (Chairman and CEO:Gyo Sagara, "Ono") today announced that it has successfully completed the tender offer, previously announced on April 30, 2024 to acquire all outstanding shares of common stock of a US b...
2024-06-11 20:30
1431
Meihua International Medical Technologies Co., Ltd. to Present at the Sidoti Small Cap Conference and Update Investors at the Emerging Growth Conference on June 13, 2024
YANGZHOU, China, June 11, 2024 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (Nasdaq: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries inChina, is pleased to announce that it...
2024-06-11 18:00
2849
Biosion Today Presented Key Phase 2 POC Clinical Study Results for Bosakitug, an Anti-TSLP mAb, in Atopic Dermatitis Subjects at the Revolutionizing Atopic Dermatitis Conference
NEWARK, Del. and NANJING, China, June 11, 2024 /PRNewswire/ -- Biosion, a global, clinical-stage biotechnology company,today presented key results from the ADAMANT study, a phase 2 proof-of-concept trial in AD subjects treated with Bosakitug, a high potency anti-TSLP mAb, in a podium presentation...
2024-06-11 18:00
1368
111, Inc., Scrianen Announce Strategic Direct Supply Partnership to Expand Nationwide Reach and Improve Drug Accessibility
SHANGHAI, June 11, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, announced that the Company has ent...
2024-06-11 15:57
3317
HKBU-led research predicts humidity trends will result in widespread heat stress in China
HONG KONG, June 11, 2024 /PRNewswire/ -- A study conducted by a research team led by Hong KongBaptist University (HKBU) has discovered that there is a trend of increasing humidity in the northern part ofChina which is not observed in the south. This phenomenon will ultimately become a prominent f...
2024-06-11 14:59
1810
ITC final initial determination Ruled in favor of Hugel (no violation of Section 337)
SEOUL, South Korea, June 10, 2024 /PRNewswire/ -- Hugel Inc, a global total medical aesthetics company, announced that the Administrative Law Judge (ALJ) for its U.S. International Trade Commission(ITC) investigation issued an initial determination onJune 10th (local time) finding that "there is ...
2024-06-11 11:33
1734
Gannex Announces Poster Presentation of Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy-Confirmed MASH at EASL CONGRESS 2024
--Up to 68.2% mean relative reduction in liver fat content from baseline among biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients receiving 12-week treatment of ASC41 --Significant and clinically meaningful reductions in liver fat, alanine aminotransferase(ALT), as...
2024-06-11 08:10
1854
Full-Life Technologies Disclosed Preclinical Data of its NTSR1-targeting RDC Program FL-091 in an Oral Presentation at the 2024 SNMMI Annual Meeting
SHANGHAI and HEIDELBERG, Germany, June 10, 2024 /PRNewswire/ -- Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, released preclinical data of its NTSR1-targeting RDC program FL-091 in an oral presentation at the 2024 SNMMI (The Society of Nuclear Medicine a...
2024-06-11 08:00
1586
Smartee Successfully Hosts GS Mandibular Repositioning Conference in Spain
MADRID, June 10, 2024 /PRNewswire/ -- The Smartee GS Mandibular Repositioning Technology Conference was successfully held inMadrid, Spain. This gathering provided a unique space for international dental professionals to engage in in-depth dialogue and exchange ideas on Smartee's innovative S8 ort...
2024-06-10 21:19
1351
Kangpu Biopharmaceuticals to Present Results from Phase 2a of KPG-818 in SLE at EULAR 2024
HEFEI, China, June 10, 2024 /PRNewswire/ -- Kangpu Biopharmaceuticals today announced that a poster tour presentation highlighting the Phase 2a clinical data of KPG-818 in patients with Systemic Lupus Erythematosus (SLE) will be presented at the upcoming Annual European Congress of Rheumatology E...
2024-06-10 20:00
1829
FDA Grants Fast Track Designation to GCBP and Novel Pharma's GC1130A
* FDA's Fast Track designation speeds up the development of new biologic drugs for rare diseases YONGIN, South Korea, June 10, 2024 /PRNewswire/ -- GC Biopharma (006280. KS) and Novel Pharma have announced that the U.S. FDA has granted Fast Track Designation for their jointly developed MPSIIIA ...
2024-06-10 16:18
2147
J INTS BIO, ASCO 2024 - JIN-A02 showed tumor reductions including brain metastasis in the ongoing first-in-human, dose-finding Phase 1 clinical study
SEOUL, South Korea, June 10, 2024 /PRNewswire/ -- J INTS BIO provided an update of its ongoing Phase 1 clinical study of JIN-A02, a 4th generation EGFR-TKI for NSCLC treatment, during the 3rd of June poster session of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting held at Mc...
2024-06-10 13:56
1681
DeepQure receives IDE Approval from FDA for its EFS study to treat Resistant Hypertension with its Extravascular Renal Denervation Technology (HyperQure™)
SEOUL, South Korea, June 10, 2024 /PRNewswire/ -- DeepQure, a Seoul based medical device company with a novel, extravascular (laparoscopic approach) solution for renal denervation (RDN), today announced initiation of its Early Feasibility Study (EFS) for the HyperQure™ system following FDA IDE ap...
2024-06-10 13:14
1643
United Imaging Prepares to Ship its 30,000th Unit Globally, a uMI Panorama GS, from Houston for U.S. Installation
The uMI Panorama GS is among the all-digital Molecular Imaging systems United Imaging is featuring at SNMMI in Toronto SHANGHAI, June 8, 2024 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, is on the brink of a significant milestone as it a...
2024-06-08 21:00
4108
Tsingke Concludes a Successful Showcase at TIDES USA 2024: Advancing Biotechnology Frontiers
BEIJING and PARIS, June 7, 2024 /PRNewswire/ -- Tsingke
2024-06-07 22:09
4266
Amorepacific Hosts NBRI Symposium
Announces Results of Skin Aging Research Conducted in collaboration with The Johns Hopkins University School of Medicine SEOUL, South Korea, June 7, 2024 /PRNewswire/ -- Amorepacific hosted the "New Beauty Research Initiative (NBRI) Symposium" at its R&I Center in Yongin, Korea, onWednesday, Jun...
2024-06-07 21:00
4046
Qilu Pharmaceutical's Three Clinical Studies on Cancer Immunotherapy Presented at ASCO 2024
JINAN, China, June 6, 2024 /PRNewswire/ -- The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting convened fromMay 31 to June 4, 2024 in Chicago, USA, adopting a hybrid format. Among the presented works, three clinical studies from Qilu Pharmaceutical were selected for poster sessio...
2024-06-07 14:51
1635
Week's Top Stories
Most Reposted
ASTON MARTIN ARAMCO FORMULA ONE® TEAM ANNOUNCE PEPPERSTONE AS OFFICAL TRADING PARTNER
[Picked up by 308 media titles]
2025-01-07 09:00
RuggON Unveils VORTEX Vehicle Mount Computer with AI-Enhanced, SATCOM-Ready
[Picked up by 306 media titles]
2025-01-06 21:00
Brewing Connections and Spotlighting Café Culture: MIFB 2025 Hosts MNCC in Collaboration with MSCA
[Picked up by 305 media titles]
2025-01-06 14:00
iWOW Unveils Age-Tech Innovations at CES 2025, Expanding Portfolio of IoT Solutions for Ageing-In-Place
[Picked up by 294 media titles]
2025-01-07 21:18CELEBRATE THE LUNAR NEW YEAR 2025 AT HOIANA RESORT & GOLF, WORLD'S LEADING FULLY INTEGRATED RESORT
[Picked up by 290 media titles]
2025-01-06 19:25
Most Read
Interest-Driven Consumption Sparks ¥ 500B ACG Goods Market, MINISO Rides the Wave
2025-01-03 19:33
10981
